By competing with fibrinogen and von Willebrand factor (vWF) for GP<unk> /IIIa binding, GP<unk> /IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation
Mostly indicated for patients undergoing PCI for ACS
Glycoprotein IIB/IIIA inhibitor
C1 inhibitor
Anticoagulants
DPP-4 inhibitors
SGLT-2 Inhibitor
ACE inhibitor
Antiplatelet medications
Anti-platelet agent reversal